MacroGenics Inc (NASDAQ:MGNX) experienced a modest after-hours uptick, rising 1.3% on Monday after Sanofi confirmed a $24.5 million regulatory milestone payment to the clinical-stage biopharmaceutical company.
The payment followed the U.S. Food and Drug Administration's decision to grant accelerated approval to TZIELD (teplizumab-mzwv) for a new indication: delaying the decline in endogenous insulin production in children aged eight to 17 years who have recently been diagnosed with stage 3 type 1 diabetes. That regulatory action expands the approved use for TZIELD as a disease-modifying therapy in the type 1 diabetes treatment landscape.
Under the licensing terms between MacroGenics and Sanofi, the $24.5 million transfer is the latest in a series of contingent payments tied to regulatory events. MacroGenics remains eligible for up to $305 million in additional milestone payments set out in the agreement. The company also retains the right to receive a single-digit royalty on global net sales of TZIELD once sales exceed a specified annual threshold.
TZIELD is described as a CD3-directed monoclonal antibody and is noted in the regulatory filings as the first disease-modifying therapy approved for autoimmune type 1 diabetes. The drug was initially approved in the United States in November 2022 for use to delay the onset of stage 3 type 1 diabetes in adults and in children eight years and older diagnosed with stage 2 type 1 diabetes.
Beyond recent U.S. approvals, TZIELD already holds approvals in multiple jurisdictions for adults and children aged eight years and older with stage 2 disease. Those included markets listed by Sanofi are the United Kingdom, the European Union, China, Australia, Canada, Israel, Saudi Arabia, the United Arab Emirates, Kuwait, Brazil and Switzerland.
MacroGenics is a clinical-stage company focused on developing antibody-based therapies, with a stated emphasis on treatments for cancer. In its partnership with Sanofi, MacroGenics has structured potential future payments and royalty participation rather than direct commercial responsibility for the product in most markets.
Market reaction and context
The share movement reflected the market response to a near-term cash inflow tied to regulatory progress for a partnered asset. The payment itself was directly linked to the FDA action and does not represent an upfront sale or an equity transaction.
Further monetary benefits to MacroGenics depend on the attainment of unspecified additional milestones and the achievement of commercial thresholds that would trigger royalty payments.